Research indicates the TET2 genetic variant reduces acute myeloid leukemia risk by 60%, advancing precision oncology strategies and prompting healthcare…
Memorial Sloan Kettering’s AI clinical trial data shows improved patient matching and operational efficiency
Memorial Sloan Kettering’s AI system achieved 100% accuracy in patient matching for clinical trials, identifying all manually screened candidates and…
European biotech secures $80 million to advance AI-driven cancer drug discovery
CHARM Therapeutics’ Series B funding highlights Europe’s growing leadership in AI-powered drug development, focusing on novel oncology treatments using advanced…
NUCLIDIUM’s €84M boost positions Europe at forefront of precision cancer therapy
European biotech NUCLIDIUM secured €84M Series B funding to advance copper-based radiopharmaceutical cancer treatments, highlighting Europe’s precision medicine leadership through…
Macmillan cancer support invests in virtual cancer clinic to expand access to care
Macmillan Cancer Support has invested in Perci Health, a virtual clinic offering personalized cancer care programs, aiming to enhance multidisciplinary…
Johnson & Johnson tops hedge funds’ list of best cancer stocks to buy
Johnson & Johnson (JNJ) is highlighted as a top cancer stock by hedge funds, driven by the booming oncology market…
Johnson & Johnson emerges as top cancer stock pick among hedge funds amid booming oncology market
Johnson & Johnson (JNJ) is favored by hedge funds as a leading cancer stock, driven by the rapidly growing oncology…
Johnson & Johnson’s Strategic Maneuvers in Oncology Market
Johnson & Johnson strengthens its role in the booming oncology market, aligning with the anticipated surge in global cancer drug…
Johnson & Johnson Leads in Transformative Cancer Treatments
Johnson & Johnson’s (JNJ) leadership in cancer treatment innovations is attracting significant hedge fund investments, amidst projections of a burgeoning…
Johnson & Johnson Leads Investment in Cancer Treatment Breakthroughs
Johnson & Johnson spearheads major investments in oncology, projecting the market could soar to $518.25 billion by 2032. Johnson &…
AI trial enhances precision of radiotherapy for prostate cancer
The Clatterbridge Cancer Centre is leveraging AI to refine radiotherapy for prostate cancer, building on the PIVOTALboost trial’s findings. This…